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nocturnal hemoglobinuria patients treated or not
by eculizumab
Focus on platelet extracellular vesicles
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Abstract
Thrombosis are severe complications of paroxysmal nocturnal hemoglobinuria (PNH), effectively reduced by eculizumab.
Extracellular vesicles (EVs) may play a central role. The objective of this study was to assess the procoagulant activity of plasma
isolated from PNH patients (treated or not by eculizumab) and to quantify their circulating EVs.
We iteratively collected the platelet-free-plasma of 17 PNH patients and 16 matched healthy volunteers, quantiﬁed their circulating
EVs by ﬂow cytometry and evaluated their procoagulant activity by thrombin generation and STA-Procoag-procoagulant
phospholipid (PPL) assays.
A signiﬁcant decrease of EVs from platelets (P= .024) and an increase of the STA-Procoag-PPL clotting time (P= .049) was
observed after initiation of eculizumab and up to 11 weeks after. This reduction of prothrombotic biomarkers was not observed with
the thrombin generation test due to a lack of sensitivity of this assay. Active hemolysis was observed in 90% of patients and elevated
D-dimers in 41% of them. However, no signiﬁcant difference was observed between patients and control subjects regarding the
procoagulant activity, the EVs quantity, or the cellular origin. Lactate dehydrogenase (LDH) levels were lower in eculizumab-treated
patients compared to nontreated patients (441 vs 2448 IU/L). D-dimers and LDH decreased after administration of eculizumab (mean
decrease of 1307ng/mL and 4159 IU/L, respectively).
These observations suggest a decrease of the phospholipid-dependent procoagulant potential of EVs after eculizumab therapy in
PNH patients.
Trial registration: NUB: B039201214365
Abbreviations: CAT= calibrated automated thrombogram, EV= extracellular vesicle, ISTH= International Society of Thrombosis
and Hemostasis, LDH= lactate dehydrogenase, NPP = normal pooled plasma, PEVs= extracellular vesicles of platelet origin, PFP =
platelet-free plasma, PNH = paroxysmal nocturnal hemoglobinuria, PPL = procoagulant phospholipid, RBC = red blood cell, TF =
tissue factor.
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11. Introduction
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired
disorder of the pluripotent hematopoietic stem cell due to an
increased sensitivity toward attack of the complement, resulting
of intravascular hemolysis. Venous and arterial thrombotic
events are frequent and making the complications of the disease
challenging to treat. Before the discovery and the generalization
of eculizumab therapy, 40% to 67% of PNH patients died of
thrombotic complications.[1]
The exact pathophysiology of thrombosis in PNH is still
unknown but probably multifactorial and extracellular
vesicles (EVs) may play a central role.[2] In previous studies,
increased levels of circulating EVs have been measured in PNH
patients,[3–7] a majority of them coming from platelets.[3] Platelets
EVs [extracellular vesicles of platelet origin (PEVs)] are known in
vitro to have a 50- to 100-fold higher procoagulant activity than
activated platelets.[8] Eculizumab, a humanized monoclonal
antibody directed against the complement protein C5, has
demonstrated its efﬁcacy in preventing the occurrence of
thromboembolic events in PNH.[9] The mechanisms involved
remain misunderstood.
Devalet et al. Medicine (2019) 98:27 MedicineOur hypothesis is that eculizumab is able to prevent an
excessive release of EVs in PNH patients, reducing their
procoagulant potential.
The objective of this study is thus to assess the procoagulant
activity of plasma isolated from PNH patients, treated or not by
eculizumab, and to characterize their circulating EVs in terms of
quantity and cellular origin. We aim at comparing the same
parameters measured simultaneously in healthy subjects and in
PNH patients to monitor the impact of eculizumab on these
parameters in PNH patients.2. Materials and methods
2.1. Study design and patients
This clinical trial was monocentric, prospective, and observa-
tional. It was approved by our central ethics committee
(Commission d’Ethique Biomédicale Hospitalo-Facultaire de
l’UCL) and was in accordance with the Helsinki Declaration.
After informed consent, patients aged of 18 years or older and
suffering from PNH with a PNH clone measured by ﬂow
cytometry of at least 5% were able to be included in the study.
Patients could be treated or not by eculizumab at the time of
inclusion. The inclusion period started in December 2012 and
stopped in July 2014. Pregnant patients or patients who
underwent hematopoietic stem cell transplantation were
excluded.
Blood tests were performed at inclusion and repeated 6
months, 1 year, and 2 years later. The induction phase of
eculizumab therapy consists of 4 infusions of 600mg once a
week, followed by a 900mg infusion every 2 weeks in
maintenance. For patients starting eculizumab during follow-
up (decision left to the treating hematologist), the blood was
collected just before the ﬁrst infusion of 600mg, at 5 weeks just
before the ﬁrst dose of 900mg and at 11±2 weeks during
maintenance treatment.
At each inclusion of a PNH patient, a healthy volunteer of
similar sex and age was simultaneously included in the study.
Blood samples from PNH patient and healthy volunteer were
analyzed together. These healthy volunteers were only seen at
inclusion, should not suffer from any active disease and should
not have a personal history of thrombosis. In addition,
pregnancy, tobacco consumption, and treatment with antiplate-
let agents, nonsteroidal anti-inﬂammatory drugs, or anticoagu-
lants within 10 days before inclusion, were exclusion criteria.
PNH patients had to come to the Hematology Laboratory of
CHU UCL Namur (Godinne site) in Belgium to undergo a blood
test at each time point of the study. The same blood test was
performed at inclusion for healthy volunteers. Clinical character-
istics were collected for each PNH patient: age, sex, weight,
height, and medical and surgical history including thrombosis,
transfusion history, and drug treatment.
The blood was collected by venipuncture in the antecubital
vein, in the morning, in a fasting state, after 30 minutes at rest,
and at the hematology laboratory. The blood collection was
performed in agreement with the recommendations of the
International Society of Thrombosis and Hemostasis (ISTH)
regarding the preanalytical conditions for EVs characteriza-
tion.[10]
A portion of the collected blood served for routine hematology
(Sysmex XN-9000, Kobe, Japan), chemistry analysis (VITROS
5600 Integrated System, Ortho Clinical Diagnostics, Raritan, NJ)2and D-dimers quantiﬁcation (Stago, Asnière-sur-Seine, France).
PNH clone size was determined by analysis of neutrophils,
monocytes, and red blood cells (RBC) in ﬂow cytometry, in
agreement with international guidelines.[11,12] Glomerular ﬁltra-
tion rate was estimated using the Modiﬁcation of Diet in Renal
Disease (MDRD) formula.2.2. Platelet-free plasma and normal-pooled plasma
Three citrated tubes (Greiner bio-one, 3.5mL, Sigma-Aldrich,
Darmstadt, Germany) per patient or healthy volunteer were used
for EVs analyses. According to the ISTH recommendations,[10]
the tubes were centrifuged at 2500g for 15 minutes at room
temperature. After this, the supernatantwas pipetted and placed in
a second tube, then centrifuged again under the same conditions.
The second supernatant [platelet-free plasma (PFP)] was then
pipetted, distributed in aliquots of 500mL in low temperature
freezer vials (VWR International bvba, Leuven, Belgium) and
frozen without delay at 80°C. After thawing in a water bath at
37°C for 4minutes, samples were used in the different experiments
[for hemolysis measurement and characterization of EVs by ﬂow
cytometry, thrombin generation, and STA-Procoag-procoagulant
phospholipid (PPL) assays]. It was previously demonstrated that
deepfreeze storage conditionsdonot strongly inﬂuenceEVanalysis
when performed adequately.[13]
It is important to note that a further concentration step of EVs
by ultracentrifugation was later applied for thrombin generation
assay (see below) but not for hemolysis measurement, ﬂow
cytometry, and STA-Procoag-PPL analysis. This was performed
to ﬁnd a solution to the lack of sensitivity of thrombin generation
assay.[14]
The use of a normal pooled plasma (NPP) from other healthy
volunteers was required to assess the impact of EVs on thrombin
generation. For this purpose, the whole blood of 47 healthy
subjects was collected on the same day by venipuncture. These
samples were centrifuged twice at 2500g during 15 minutes at
20°C. After pooling, the NPP was quickly frozen in liquid
nitrogen and stored at 80°C.2.3. Harboe’s direct spectrophotometric method for
hemolysis measurement
Two hundred microliters of each sample was placed in a cuvette
(Sarstedt AG&Co., Nümbrecht, Germany), and 1800mL of
distilled water was added, giving a 10-fold dilution of the sample.
A pipette was used for gentle mixing followed by resting for 10
minutes. The absorbance of each sample was read at 3 different
wavelengths (380, 415, and 450nm) against a distilled water
blank in the spectrophotometer (Genesys 10S UV-Vis, Thermo
Fisher Scientiﬁc Inc, Waltham, MA). The absorbance was
converted into free hemoglobin concentration according to
Han et al[15] before calculating the degree of hemolysis. This last
value was calculated by taking into account the hematocrit and
total hemoglobin level.2.4. Flow cytometry
Samples were analyzed on an FACS Aria ﬂow cytometer with
FACSDiva V6.1.3 software (BD Biosciences, San Jose, CA). The
cytometer was optimized and programmed following the
standardized procedures for measurement of EVs provided by
the ISTH.[16–18]
Devalet et al. Medicine (2019) 98:27 www.md-journal.comThe cytometer was calibrated with Megamix-Plus SSC beads
(BioCytex, Marseille, France). These beads are optimized for use
on cytometer FACS Aria.[18] The separation index was used to
evaluate the resolution on SSC parameter.[19]
Themonoclonal antibodies usedwereCD235a-PE (IOTest, clone
11E4B-7-6, Beckman Coulter, Marseille, France), CD31-V450
(cloneWM59, BD Biosciences, Erembodegem, Belgium), CD33-PE
(clone P67.6, BD Biosciences), CD14-V450 (clone MfP9, BD
Biosciences), CD41a-PerCP-Cy5.5 (clone HIP8, BD Biosciences).
Annexin V-FITC (BD Pharmingen, Erembodegem, Belgium) was
used to tag phosphatidylserine present at EVs’ surface.
Before use, each monoclonal antibody was centrifuged at
15,000g for 10 minutes at 4°C to remove antibodies aggregates.
They were stored at 4°C to 6°C in the dark until use (within 4
hours). Samples were thawed in a water bath at 37°C for 4
minutes, just before incubation with antibodies, for 30minutes at
room temperature in the dark.
Then, the samples were introduced in the ﬂow cytometer. The
number of events during the acquisition period of 120seconds
was recorded. With an identical volume of sample and a constant
ﬂow during each analysis (5.4mL/min), the absolute concentra-
tion of EVs could be calculated.2.5. Calibrated automated thrombogram
The thrombin generation tests were performed on a Fluoroskan
Ascent (Thermo Scientiﬁc, Waltham, MA) using the Thrombino-
scope software (v 3.0, Thrombinoscope BV, Maastricht, The
Netherlands). Each sample was run in triplicates.
2.5.1. Concentration of EVs. To isolate EVs, samples were
placed in a microcentrifuge polyallomer tube (Beckman Coulter,
Marseille, France) and ultracentrifuged at 100,000g for 90
minutes at 4°C. The pellet of EVs was suspended in a volume of
supernatant to concentrate EVs 6.7 times more than that in the
PFP. This further concentration step of EVs was needed to trigger
thrombin generation assay without the addition of any reagents
containing tissue factor (TF) or phospholipids. The tubes were
spun for 1 minute and were stored on ice until being plated for
calibrated automated thrombogram (CAT) analysis.
To evaluate the possible impact of TF bearing vesicles, anti-TF
antibody (puriﬁed mouse anti-human CD142, BD Bioscience,
Erembodegem, Belgium) was added to the concentrate of EVs at a
ﬁnal concentration of 10mg/mL. This mixture was incubated
during 10 minutes at 37°C.
2.5.2. Thrombin generation assay. Twenty microliter of EVs
concentrate, 20mL of EVs concentrate with anti-TF, and 20mL of
the supernatant of EVs concentrate were tested. Twenty
microliter of thrombin calibrator was added to 3 other wells.
For interplate quality control, 3 wells contained 20mL of PPP-
Reagent Low (Thrombinoscope BV), constituted of TF and
phospholipids.
The plate was then incubated for 10minutes in the CAT system
at 37°C and during this time, the NPPwas thawed in a water bath
at 37°C. Afterwards, 80mL of NPP was added to each well and
20mL of FluCa (mix of ﬂuo-buffer and ﬂuo substrate)
(Thrombinoscope BV) were added by the dispenser.2.6. STA-Procoag-PPL
The STA-Procoag-PPL kit (Diagnostica Stago SAS, Asnières-sur-
Seine, France) is designed for the detection of PPLs in plasma3samples by a chronometric method. This assay measures clotting
time, in the presence of factor Xa and CaCl2, of a system in which
all the factors are present at physiological levels (supplied by PPL
depleted plasma) except the PPL supplied by the plasma sample
being tested.[20]
Five hundred microliters of each PFP sample was placed in a
cuvette and introduced in a STA-R Evolution coagulometer
(Diagnostica Stago SAS).2.7. Statistical analysis
Quantitative data are described with median and range.
P values are computed with the Wilcoxon signed rank test
or Wilcoxon rank sum test for independent and paired data,
respectively. Statistical analyses are performed with R 3.3.2
software (R Foundation for Statistical Computing, Vienna,
2016).3. Results
3.1. Patients’ characteristics
After informed written consent, 17 PNH patients and 16
healthy volunteers were included in the study. It was not
possible to ﬁnd a sex/age-matched healthy volunteer to include
simultaneously with patient 14. At inclusion, 7 of the 17 PNH
patients (P02, P04, P06, P08, P10, P13, and P15) were
chronically treated by eculizumab. Four more patients (P01,
P05, P12, and P14) started eculizumab therapy during follow-
up. The sex ratio M/F was 5/12. The median age of PNH
patients was 44 (range: 22–79) years. A personal history of
thrombosis was reported in 6 patients: 2 portal vein thrombosis
(P05 and P12), including 1 with pulmonary embolism (P05), 2
deep vein thrombosis (P13 and P17), and 2 superﬁcial vein
thrombosis (P08 and P11) (Table 1). Three patients were
treated by low-dose corticosteroids (P01, P10, P14), 2 patients
by low-dose acetylsalicylic acid (P03, P11), and 3 patients by
vitamin K antagonists (P09, P12, and P13). The median PNH
clone was 93.0% on neutrophils (min 22.5%, max 99.7%),
92.5% on monocytes (min 0.1%, max 99.8%), and 41.4% on
RBC (min 4.1%, max 68.1%).3.2. Impact of eculizumab therapy on PNH patients
We observed a signiﬁcant decrease of EVs of platelet origin
(PEVs, deﬁned as CD41+ EVs in ﬂow cytometry) after
initiation of eculizumab therapy (P= .024). A ﬁrst decrease
was observed after 4 weeks of eculizumab therapy (mean
5003PEVs/mL), which corresponds to the end of the
induction treatment phase, and a second decrease after 11
±2 weeks of treatment (mean change from baseline 7352
PEVs/mL). A parallel evolution of annexin V positive (+) PEVs
and annexin V negative () PEVs was observed. This is
illustrated in Figure 1. There was no clear tendency in the
evolution of the other subgroups of EVs. Along with this, we
observed during the study a signiﬁcant increase of the STA-
Procoag-PPL clotting time in the group that has started
eculizumab therapy compared to the group of nontreated
patients (P= .049). The mean increase in the STA-Procoag-
PPL clotting time was 11.2 seconds at 4 weeks and 27.8
seconds at 11 weeks (Fig. 2). However, this tendency was not
observed in any of the 4 parameters measured with the
Table 1
Demographic and clinical characteristics of study paroxysmal nocturnal hemoglobinuria patients.
Patient Age, y Sex Eculizumab at inclusion Eculizumab during follow-up Thrombotic history
P01 27 F x
P02 37 F x x
P03 73 M
P04 60 F x x
P05 31 F x PVT + PE
P06 44 F x x
P07 33 F
P08 45 F x x SVT
P09 44 M
P10 27 F x x
P11 68 F SVT
P12 70 F x PVT
P13 40 M x x DVT
P14 79 F x
P15 28 M x x
P16 22 F
P17 49 M DVT
DVT=deep vein thrombosis; PE=pulmonary embolism; PNH=paroxysmal nocturnal hemoglobinuria; PVT=portal vein thrombosis; SVT= superﬁcial vein thrombosis.
Devalet et al. Medicine (2019) 98:27 Medicinethrombin generation assay (data not shown), as illustrated in
Figure 3. A reduction of D-dimers levels was observed
after the induction phase of treatment (mean decrease of 1307
ng/mL).Figure 1. Decrease of the number of platelet-derived extracellular vesicles detecte
A, B, and C, The extracellular vesicles of platelet origin (PEVs) detected just before e
(B), and at 11 weeks during maintenance treatment (C) are shown according to the
blue and annexin V positive PEVs in green. A ﬁrst than a second decrease of all
detected before eculizumab (D), at 5 weeks (E), and 11 weeks after treatment in
4In addition, neutrophils and platelets counts were found to
decrease after initiation of eculizumab therapy. As expected,
hemoglobin and hematocrit levels increased while free hemoglo-
bin and reticulocytes levels decreased. Simultaneously, lowerd by ﬂow cytometry in patient 1 before and after eculizumab treatment initiation.
culizumab treatment initiation (A), at 5 weeks just before the ﬁrst dose of 900mg
ir labeling by annexin V and anti-CD41. Annexin V negative PEVs are shown in
PEVs is observed after initiation of eculizumab. D, E, and F, The total of PEVs
itiation (F) are shown according to their count and their labeling of CD41.
Figure 2. Evolution of PEVs (ﬂow cytometry) and clotting time (STA-Procoag-PPL) after eculizumab treatment in PNH patients. This ﬁgure illustrates the evolution of
the number of PEVs detected by ﬂow cytometry (full lines) and the clotting time measured in STA-Procoag-PPL assay (dotted lines) after the start of eculizumab.
Eculizumab was administered just after the ﬁrst blood sample. An evolution in mirror of these 2 parameters can be observed. PEV=extracellular vesicle of platelet
origin; PNH=paroxysmal nocturnal hemoglobinuria.
Devalet et al. Medicine (2019) 98:27 www.md-journal.comlevels of lactate dehydrogenase (LDH) were measured (mean
decrease of 4159IU/L), indicating a reduction in hemolysis.
PNH clone size was not signiﬁcantly impacted by initiation of
eculizumab therapy when measured on neutrophils and mono-Figure 3. Evolution of the amount of thrombin generated (CAT curves) before
and after eculizumab treatment in paroxysmal nocturnal hemoglobinuria (PNH)
patient 14. This ﬁgure illustrates, in patient 14, the evolution of the amount of
thrombin generated during the reaction time with CAT before eculizumab (in
grey), 4 weeks (in light blue), and 11 weeks (in dark blue) after starting
treatment. Even if a slight decrease of the lagtime and an increase of the area
under the curve (endogeneous thrombin potential) were observed after 11
weeks of eculizumab, this was not observed consistently in the other 3
patients. CAT=calibrated automated thrombogram.
5cytes but there was a tendency to an increase of PNH clone
measured on RBC.3.3. Comparison of PNH patients not treated by
eculizumab and their matched controls
Routine hematology and chemistry analysis revealed some
signiﬁcant differences in PNH patients not treated by eculizumab
compared with healthy volunteers (Table 2). Lower levels of
platelets and lymphocytes were observed in untreated PNH
patients than in control subjects (about 2-fold decrease).
Regarding to hemolysis parameters, lower hemoglobin and
hematocrit levels and higher LDH and reticulocytes levels were
observed in PNH patients compared to controls. Moreover, the
haptoglobin level was not measurable (<3.5mg/dL) in 89% of
untreated PNH patients, whereas it was never lowered in control
subjects. The free hemoglobin concentration was higher in PNH
patients than in control subjects. Renal function was not different
in PNH patients compared to controls.
In terms of procoagulant activity, D-dimers were elevated
(>500ng/mL) in 66.7% of the untreated PNH patients but in
none of the controls. However, the procoagulant activity
measured by either thrombin generation or STA-Procoag-PPL
assays was not signiﬁcantly different between untreated PNH
patients and control subjects.
It is important to note that variability was observed in results
obtained within the triplicates in thrombin generation assay
(mean interwells coefﬁcient of variation: 15.7%). Moreover, the
addition of anti-TF antibody to the wells was associated with a
Table 2
Description of measured parameters for paroxysmal nocturnal hemoglobinuria patients treated or not by eculizumab and their matched
controls.
PNH patients not treated by
eculizumab compared to their controls
Median (min; max)
PNH patients treated by eculizumab
compared to their controls
Median (min; max)
HPN0 (n=9) CTL0 (n=9) HPN1 (n=7) CTL1 (n=7)
P
HPN0
vs CTL0
P
HPN1 -CTL1 vs
HPN0-CTL0
White blood cells, /mL 4500 (2900; 6400) 5800 (4900; 7400) 3900 (2400; 6900) 5400 (3500; 7100) .055 .92
Neutrophils, /mL 2700 (1300; 5400) 2900 (2100; 4100) 1800 (1100; 4200) 3200 (1800; 4300) .82 .54
Platelets, /mL 139,000 (66,000;
198,000)
272,000 (211,000;
373,000)
176,000 (94,000;
275,000)
264,000 (172,000;
382,000)
.004
∗
.35
Hemoglobin, g/dL 12.1 (8.1; 14.1) 14.1 (11; 16.4) 11.3 (9.8; 12.1) 13.4 (12.1; 16) .027
∗
.63
Hematocrit (%) 37.4 (24.8; 41.7) 41 (34.7; 46.4) 35.1 (32.2; 37.5) 40.6 (36.8; 47.2) .027
∗
1
LDH, UI/L 2448 (640; 11,370) 433 (342; 632) 441 (378; 648) 458 (330; 537) .004
∗
.0003
∗
Haptoglobin, mg/dL 3.5 (3.5; 77.7) 91.6 (51.1; 116.6) 3.5 (3.5; 34.6) 114.8 (86.7; 128.8) .008
∗
.14
Free hemoglobin
concentration, mg/dL
10.7 (0; 94.3) 0.8 (0; 6.5) 4.8 (0.3; 19.2) 1.8 (0; 6.9) .004
∗
.042
∗
GFR, mL/min 77.5 (53.3; 146.6) 95.0 (65.6; 108.4) 131.7 (74.5; 184.8) 90.3 (74.6; 115.0) .91 .055
D-dimers, ng/mL 600 (220; 1770) 270 (220; 470) 320 (260; 680) 270 (220; 390) .042
∗
.31
ETP in TGA, nM 627 (362; 763) 743 (305; 1094) 478 (110; 873) 715 (149; 971) .098 1.00
Clotting time in STA-
Procoag-PPL assay, s
74.4 (53.4; 86.5) 66.6 (57.2; 115.2) 65.9 (48.9; 78.7) 67.1 (46.3; 102.9) .73 .84
PNH clone on neutrophils (%) 83.6 (22.5; 99.7) 94.4 (58.0; 99.5) .30
PNH clone on monocytes (%) 87.8 (28.7; 99.6) 93.0 (0.05; 99.2) .61
PNH clone on RBC (%) 29.0 (4.5; 58.4) 53.1 (39.0; 68.1) .14
CTL0= control subjects matched to PNH patients not treated by eculizumab, CTL1= control subjects matched to PNH patients treated by eculizumab, ETP= endogenous thrombin potential, GFR=glomerular
ﬁltration rate, HPN0=PNH patients not treated by eculizumab, HPN1=PNH patients treated by eculizumab, LDH= lactate dehydrogenase, PNH=paroxysmal nocturnal hemoglobinuria, PPL=procoagulant
phospholipid, RBC= red blood cells, TGA= thrombin generation assay.
Devalet et al. Medicine (2019) 98:27 Medicinelengthening of the lagtime in only 37%of the control subjects and
in 29% of PNH patients.
The EVsmeasured in ﬂow cytometry did not differ signiﬁcantly
in term of quantity or surface antigens in untreated PNH patients
and control subjects.
3.4. Comparison of PNH patients treated by eculizumab
and their matched controls
Globally, the differences observed between treated PNH patients
and their controls appeared similar to those observed between
untreated PNH patients and their relative control, except for
LDH, free hemoglobin, and D-dimer levels (Table 2).
The haptoglobin level was not measurable in 91.7% of treated
PNHpatients, while always normal in control subjects. However,
the LDH levels measured in treated patients were comparable to
controls. Free hemoglobin concentration increased less in treated
patients than in untreated patients. D-dimers were elevated in
only 16.7% of the eculizumab treated PNH patients compared to
66.7% in untreated patients.
Of note, changes in thrombin generation parameters, clotting
time in STA-Procoag-PPL and characteristics of EVs between
treated PNH patients were similar to the ones observed between
untreated PNH patients and matched controls.
The PNH clone measured on neutrophils or monocytes was
similar in eculizumab treated and not treated PNH patients.
More relevant differences were observed on RBC, with a mean of
53.1% in treated patients versus 29.0% in nontreated patients.
4. Discussion
In this prospective and comparative study of PNH patients, we
observed a signiﬁcant decrease of the number of PEVs measured6by ﬂow cytometry after initiation of eculizumab therapy, along
with an increase of the STA-Procoag-PPL clotting time. This may
reﬂect a decrease of the phospholipid-dependent procoagulant
potential of the EVs isolated from plasma of PNH patients after
eculizumab therapy.
Van Bijnen et al[21] suspected a higher level of platelet
activation induced by complement in PNH, by the fact that PNH
platelets, after membrane attack complex stimulation, expose
more FVa-binding sites and increase thrombin generation.
Platelet activation is a well-known process leading to the release
of procoagulant PEVs.[22–24] In our study, PNH patients
chronically treated by eculizumab or not treated at all do not
show a signiﬁcant difference in term of PEVs quantity or
phospholipid-dependent procoagulant activity compared to
normal subjects. These observations may be attributed to an
interindividual variability of the number of circulating EVs in
general population and in pathological states[23] and the small
number of patients included in our study. However, if we focus
on each PNHpatient who starts eculizumab therapy, the decrease
of their number of PEVs and of their phospholipid-dependent
procoagulant proﬁle appears in 3 of the 4 patients (P1, P12, P14).
The remaining patient (P5) had already a low level of PEVs before
eculizumab therapy. The decrease of the number of PEVs occurs
very quickly after the induction phase of treatment, due to the
dose intensity of eculizumab, and seems to continue to decrease
steadily during the maintenance phase of treatment. Weitz et al[7]
observed, in their study on 11 PNH patients, a decrease of sP-
selectin level after eculizumab therapy. This provides additional
argument for a decrease of platelet (and endothelial) activation
induced by complement inhibition. Platelet activation remains
difﬁcult to study, as long as a reliable plasma marker of platelet
activation has not been identiﬁed.[25] More studies are needed to
Devalet et al. Medicine (2019) 98:27 www.md-journal.comevaluate the potential of PEVs as marker of platelet activation in
PNH.
Moreover, we observed an increased level of D-dimers in PNH
patients compared to control subjects and a decrease of this
marker after initiation of eculizumab therapy. This is in
agreement with previous studies,[7,26–28] conﬁrming that D-
dimers may be a marker of hemostatic activation in PNH, even if
its lack of speciﬁcity remains a problem.
Biological parameters conﬁrm active hemolysis in most of
PNH patients included in our study. A higher LDH level was
observed in patients compared to control and it decreased during
eculizumab therapy. A retrospective analysis of 301 patients from
the South Korean National PNH Registry showed that PNH
patients with elevated LDH levels (≥1.5 the upper limit of
normal) had a signiﬁcantly higher risk of thromboembolic event
(odds ratio: 7.0; P= .013).[29] The link between hemolysis and
thrombosis in PNH is still controversial[2] but eculizumab clearly
demonstrated its efﬁcacy to reduce hemolysis.[30,31]
In this study, contrary to what we expected, we did not observe
an increase of thrombin generation in PNH patients compared to
control subjects, neither a decrease of this proﬁle after eculizumab
therapy. The lack of sensitivity of thrombin generation assay and
the variability of results obtained may limit the possibility to
detect tight variations between these groups, which are small and
heterogeneous.[14,32] The addition of small amounts of phos-
pholipids and TF may facilitate the reaction and increase its
sensitivity.[33] Moreover, the use of anti-TF pathway inhibitor
may help to reduce the intrinsic variability of this assay.[14]
Finally, we could not totally exclude an impact of free
hemoglobin, released by hemolysis, on the amount of thrombin
generated in this assay. In this ﬂuorogenic assay, free hemoglobin
may increase the absorbance of the sample. Previous studies
demonstrated that free plasma hemoglobin was able to falsely
reduce thrombin peak height in thrombin generation assays, in
direct proportion to the concentration of hemoglobin in the
sample.[27,34] However, the use of thrombin calibrator, as we did
in this study, minimizes this impact.[34]
An increased level of TF-bearing microparticles in PNH
patients, decreasing after eculizumab therapy, was previously
described but this was not correlated to changes in TF
microparticle activity or total microparticle factor Xa genera-
tion.[7] In our study, the addition of anti-TF antibodies did not
affect thrombin generation results more signiﬁcantly in PNH
patients than in control subjects, reinforcing the assumption that
most of the TF on the circulating EVs in PNH patients is
encrypted and nonfunctional.[7]
In conclusion, the simultaneous decrease of the number of
PEVs and of the phospholipid-dependent procoagulant activity
that we observed in the plasma of PNH patients newly treated by
eculizumab may partially explain the dramatic reduction of
thrombotic risk obtained by this treatment. However, this needs
to be further studied. We did not observe any signiﬁcant
difference in term of EVs or procoagulant activity (excepted D-
dimers) between PNH patients and healthy subjects or between
chronically treated and not treated PNH patients by eculizumab.
Similarly, no signiﬁcant difference was observed between patients
who previously experienced thrombosis and who did not.
Unfortunately, our study, like most prospective studies carried
on PNH patients, suffers from a lack of statistical power because
of the small number and the heterogeneity of patients studied
(including treatment or not by antithrombotic agents) and the
rarity of thrombotic events during a short follow-up period. The7observation of the impact of eculizumab on clinical and
biological parameters of each patient individually, before and
after initiation of treatment, deserves to be further extended.
Today, it is very hazardous to make connections between
biological observations and clinical risk. Nevertheless, develop-
ment of biomarkers able to predict thrombotic risk is needed and
the idea of PEVs in this role is attractive.Author contributions
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